Structure/Function Relationships Responsible for Coenzyme Specificity and the Isomerase Activity of Human Type 1 3β-Hydroxysteroid Dehydrogenase/Isomerase*

Human type 1 3β-hydroxysteroid dehydrogenase/isomerase (3β-HSD/isomerase) catalyzes the two sequential enzyme reactions on a single protein that converts dehydroepiandrosterone or pregnenolone to androstenedione or progesterone, respectively, in placenta, mammary gland, breast tumors, prostate, prostate tumors, and other peripheral tissues. Our earlier studies show that the two enzyme reactions are linked by the coenzyme product, NADH, of the 3β-HSD activity. NADH activates the isomerase activity by inducing a time-dependent conformational change in the enzyme protein. The current study tested the hypothesis that the 3β-HSD and isomerase activities shared a common coenzyme domain, and it characterized key amino acids that participated in coenzyme binding and the isomerase reaction. Homology modeling with UDP-galactose-4-epimerase predicts that Asp36 is responsible for the NAD(H) specificity of human 3β-HSD/isomerase and identifies the Rossmann-fold coenzyme domain at the amino terminus. The D36A/K37R mutant in the potential coenzyme domain and the D241N, D257L, D258L, and D265N mutants in the potential isomerase domain (previously identified by affinity labeling) were created, expressed, and purified. The D36A/K37R mutant shifts the cofactor preference of both 3β-HSD and isomerase from NAD(H) to NADP(H), which shows that the two activities utilize a common coenzyme domain. The D257L and D258L mutations eliminate isomerase activity, whereas the D241N and D265N mutants have nearly full isomerase activity. Kinetic analyses and pH dependence studies showed that either Asp257 or Asp258 plays a catalytic role in the isomerization reaction. These observations further characterize the structure/function relationships of human 3β-HSD/isomerase and bring us closer to the goal of selectively inhibiting the type 1 enzyme in placenta (to control the timing of labor) or in hormone-sensitive breast tumors (to slow their growth).

[1]  R. P. Myers,et al.  Human placental 3 beta-hydroxy-5-ene-steroid dehydrogenase and steroid 5----4-ene-isomerase: purification from mitochondria and kinetic profiles, biophysical characterization of the purified mitochondrial and microsomal enzymes. , 1989, Journal of steroid biochemistry.

[2]  W. Nash,et al.  Site-directed mutagenesis identifies amino acid residues associated with the dehydrogenase and isomerase activities of human type I (placental) 3β-hydroxysteroid dehydrogenase/Isomerase 1 Supported by NIH Grant HD20055 (JLT). 1 , 1998, The Journal of Steroid Biochemistry and Molecular Biology.

[3]  R. P. Myers,et al.  Human placental 3 beta-hydroxy-5-ene-steroid dehydrogenase and steroid 5----4-ene-isomerase: purification from microsomes, substrate kinetics, and inhibition by product steroids. , 1988, Journal of steroid biochemistry.

[4]  Jeremy Bruenn,et al.  Rational proteomics I. Fingerprint identification and cofactor specificity in the short‐chain oxidoreductase (SCOR) enzyme family , 2003, Proteins.

[5]  Takashi Suzuki,et al.  Dissecting human adrenal androgen production , 2002, Trends in Endocrinology & Metabolism.

[6]  J. Jez,et al.  Mutagenesis of 3 alpha-hydroxysteroid dehydrogenase reveals a "push-pull" mechanism for proton transfer in aldo-keto reductases. , 1998, Biochemistry.

[7]  J. Mason,et al.  Functional activity of 3beta-hydroxysteroid dehydrogenase/isomerase. , 1998, Endocrine research.

[8]  M. M. Bradford.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. , 1976, Analytical biochemistry.

[9]  A. Mildvan,et al.  Combined effects of two mutations of catalytic residues on the ketosteroid isomerase reaction. , 1990, Biochemistry.

[10]  R. Strickler,et al.  Affinity radiolabeling identifies peptides associated with the isomerase activity of human type I (placental) 3beta-hydroxysteroid dehydrogenase/isomerase. , 1997, Biochemistry.

[11]  T. N. Bhat,et al.  The Protein Data Bank , 2000, Nucleic Acids Res..

[12]  J. Mason,et al.  Structure/Function Relationships Responsible for the Kinetic Differences between Human Type 1 and Type 2 3β-Hydroxysteroid Dehydrogenase and for the Catalysis of the Type 1 Activity* , 2002, The Journal of Biological Chemistry.

[13]  P. Frey,et al.  Crystal structures of the oxidized and reduced forms of UDP-galactose 4-epimerase isolated from Escherichia coli. , 1996, Biochemistry.

[14]  J. Mason,et al.  The engineered, cytosolic form of human type I 3beta-hydroxysteroid dehydrogenase/isomerase: purification, characterization and crystallization. , 2001, Journal of molecular endocrinology.

[15]  W. Nash,et al.  An NADH-induced Conformational Change That Mediates the Sequential 3β-Hydroxysteroid Dehydrogenase/Isomerase Activities Is Supported by Affinity Labeling and the Time-dependent Activation of Isomerase (*) , 1995, The Journal of Biological Chemistry.

[16]  Chris Sander,et al.  Completeness in structural genomics , 2001, Nature Structural Biology.

[17]  R. Sheridan,et al.  Amino acid substitution of arginine 80 in 17beta-hydroxysteroid dehydrogenase type 3 and its effect on NADPH cofactor binding and oxidation/reduction kinetics. , 2002, Biochimica et biophysica acta.

[18]  A. Mildvan,et al.  Catalytic mechanism of an active-site mutant (D38N) of delta 5-3-ketosteroid isomerase. Direct spectroscopic evidence for dienol intermediates. , 1991, Biochemistry.

[19]  P A Frey,et al.  Mechanistic roles of Thr134, Tyr160, and Lys 164 in the reaction catalyzed by dTDP-glucose 4,6-dehydratase. , 2001, Biochemistry.

[20]  J. Simard,et al.  Structure and Expression of a New Complementary DNA Encoding the almost Exclusive 3β-Hydroxysteroid Dehydrogenase/Δ5-Δ4-lsomerase in Human Adrenals and Gonads , 1991 .

[21]  O. Lund,et al.  Protein distance constraints predicted by neural networks and probability density functions. , 1997, Protein engineering.